NCT05728541View on ClinicalTrials.gov

Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

367

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

February 1, 2026

Study Completion Date

March 1, 2026

Conditions
Advanced Malignant Tumors
Interventions
DRUG

SYH2043

Patients will receive SYH2043 once everyday on day 1-21 of each 28-day cycle

Trial Locations (1)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

Sponsors
All Listed Sponsors
lead

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY

NCT05728541 - Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors | Biotech Hunter | Biotech Hunter